menu
    • menu

    Company profile for DNDi

    NEW Drugs in Dev: 1
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    A not-for-profit research and development organization, DNDi works to develop new treatments for people living with neglected diseases, notably Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, pediatric HIV, and hepatitis C. Since its inception in 2003, DNDi has delivered eight new treatments, including new drug combinations for kala-azar, two fixed-dose antimalar...
    A not-for-profit research and development organization, DNDi works to develop new treatments for people living with neglected diseases, notably Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, pediatric HIV, and hepatitis C. Since its inception in 2003, DNDi has delivered eight new treatments, including new drug combinations for kala-azar, two fixed-dose antimalarials, DNDi’s first successfully developed new chemical entity, fexinidazole, approved in 2018 for the treatment of both stages of sleeping sickness.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    DNDiSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    15 Chemin Louis-Dunant 1202 Geneva
    Telephone
    Telephone
    +41 22 906 9230
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://dndi.org/
    Linkedin
    Linkedin
    https://www.linkedin.com/shareArticle?mini=true&url=https://www.dndi.org/about-dndi/contact-us/&title=Contact%20Us
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    PBP World Meeting

    Not Confirmed

    envelop Contact Supplier

    PBP World Meeting

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    DNDi, Sanofi Get CHMP Nod for Single-Dose Sleeping Sickness Tx
    DNDi, Sanofi Get CHMP Nod for Single-Dose Sleeping Sickness Tx

    27 Feb 2026

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-27-10-55-51-3246379

    PRESS RELEASE
    27 Feb 2026
    Share Share
    AN2 Therapeutics, DNDi Develop Oral Compound for Chagas Disease
    AN2 Therapeutics, DNDi Develop Oral Compound for Chagas Disease

    23 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250723721725/en/AN2-Therapeutics-and-DNDi-Collaborate-on-Clinical-Development-of-Promising-New-Oral-Compound-to-Treat-Chronic-Chagas-Disease

    BUSINESSWIRE
    23 Jul 2025
    Share Share
    Cipla, DNDi launch 4-in-1 antiretroviral treatment for children with HIV
    Cipla, DNDi launch 4-in-1 antiretroviral treatment for children with HIV

    15 Jun 2022

    // ECONOMIC TIMES

    https://health.economictimes.indiatimes.com/news/pharma/cipla-dndi-launch-4-in-1-antiretroviral-treatment-for-children-with-hiv/92216747

    ECONOMIC TIMES
    15 Jun 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search